Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Fibroblast growth factor 21 (FGF21) in children and adolescents with chronic kidney disease

Z. Gamrot, P. Adamczyk, E. Świętochowska, D. Roszkowska-Bjanid, J. Gamrot, M. Szczepańska

. 2020 ; 69 (3) : 451-460. [pub] 20200529

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21015650

Fibroblast growth factor 21 (FGF21) is one of the members of endocrine arm of FGF family. Its actions as a glucose and lipids metabolism regulator are widely known. Although the mechanism of FGF21 action in kidneys is still under investigation, FGF21 was considered as a marker of early kidney function decline. While many researchers focused on adult subjects in this matter, there are no data regarding children. Therefore, we have investigated the relationship between plasma or urine FGF21 levels and kidney function in a group of 42 pediatric patients with chronic kidney disease (CKD). Anthropometrical parameters and blood pressure were taken, routine biochemical tests were performed. The concentration of FGF21 in serum and urine was determined by enzyme immunoassay. The results revealed significantly higher serum FGF21 concentration among children from CKD group. However, serum FGF21 level was not related to gender, proteinuria, eGFR or renal replacement therapy. Urine FGF21 concentration correlated negatively with albuminuria and positively with eGFR. Documented negative correlation of FGF21 fractional excretion and eGFR is not enough to support the role of FGF21 as a biomarker for predicting kidney disease progression in children and adolescents. Other mechanisms including local kidney FGF21 production or enhanced excretion due to higher extrarenal production may result in higher urine FGF21 concentrations.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21015650
003      
CZ-PrNML
005      
20210618141659.0
007      
ta
008      
210604s2020 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934307 $2 doi
035    __
$a (PubMed)32469231
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Gamrot, Z. $u Unit of Paediatric Hematology and Oncology, Chorzow City Hospital, Chorzow, Poland
245    10
$a Fibroblast growth factor 21 (FGF21) in children and adolescents with chronic kidney disease / $c Z. Gamrot, P. Adamczyk, E. Świętochowska, D. Roszkowska-Bjanid, J. Gamrot, M. Szczepańska
504    __
$a Literatura
520    9_
$a Fibroblast growth factor 21 (FGF21) is one of the members of endocrine arm of FGF family. Its actions as a glucose and lipids metabolism regulator are widely known. Although the mechanism of FGF21 action in kidneys is still under investigation, FGF21 was considered as a marker of early kidney function decline. While many researchers focused on adult subjects in this matter, there are no data regarding children. Therefore, we have investigated the relationship between plasma or urine FGF21 levels and kidney function in a group of 42 pediatric patients with chronic kidney disease (CKD). Anthropometrical parameters and blood pressure were taken, routine biochemical tests were performed. The concentration of FGF21 in serum and urine was determined by enzyme immunoassay. The results revealed significantly higher serum FGF21 concentration among children from CKD group. However, serum FGF21 level was not related to gender, proteinuria, eGFR or renal replacement therapy. Urine FGF21 concentration correlated negatively with albuminuria and positively with eGFR. Documented negative correlation of FGF21 fractional excretion and eGFR is not enough to support the role of FGF21 as a biomarker for predicting kidney disease progression in children and adolescents. Other mechanisms including local kidney FGF21 production or enhanced excretion due to higher extrarenal production may result in higher urine FGF21 concentrations.
650    _2
$a mladiství $7 D000293
650    _2
$a biologické markery $x krev $x moč $7 D015415
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblastové růstové faktory $x krev $x moč $7 D005346
650    _2
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a chronická renální insuficience $x krev $x patologie $x moč $7 D051436
655    _2
$a časopisecké články $7 D016428
700    1_
$a Adamczyk, P. $u Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland
700    1_
$a Świętochowska, E. $u Chair and Department of Medical and Molecular Biology, The School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland
700    1_
$a Roszkowska-Bjanid, D. $u Pediatric Nephrology Ward, Public Clinical Hospital No. 1 in Zabrze, Poland
700    1_
$a Gamrot, J. $u Student's Scientific Society, Department of Pediatrics, The School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland
700    1_
$a Szczepańska, M. $u Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 69, č. 3 (2020), s. 451-460
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32469231 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20210604 $b ABA008
991    __
$a 20210611192658 $b ABA008
999    __
$a ok $b bmc $g 1664031 $s 1136058
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 69 $c 3 $d 451-460 $e 20200529 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20210604

Najít záznam

Citační ukazatele

Možnosti archivace